Nom du produit:8-Fluoro-3,4-dihydro-1H-spiro[naphthalene-2,2'-[1,3]dioxolan]-6-ol
IUPAC Name:8'-fluoro-3',4'-dihydro-1'H-spiro[1,3-dioxolane-2,2'-naphthalen]-6'-ol
- CAS：2489407-88-5
- Formule moléculaire：C12H13FO3
- Pureté：95%
- Numéro de catalogue：CM1046486
- Poids moléculaire：224.23
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:2489407-88-5
- Formule moléculaire:C12H13FO3
- Point de fusion:-
- Code SMILES:FC1=C(CC2(CC3)OCCO2)C3=CC(O)=C1
- Densité:
- Numéro de catalogue:CM1046486
- Poids moléculaire:224.23
- Point d'ébullition:
- N° Mdl:
- Stockage:
Category Infos
- Spiro Compounds
- A spiro compound is a polycyclic compound in which two monocyclic rings share one carbon atom; the shared carbon atom is called a spiro atom. Spiro compounds have rigid structures, stable structures, and have special properties that general organic compounds do not possess, such as anomeric effect, spiro conjugation and spiro hyperconjugation. Compared with the monocyclic structure or the planar aromatic structure, the spiro structure has a larger three-dimensional structure; the heterocyclic spiro structure is also regarded as the biological isostere of some groups, which can change the drug to a certain extent. The water solubility, lipophilicity, dominant conformation and ADMET properties of the molecule make the optimized lead molecule easier to drug. Therefore, spiro compounds occupy a very important position in drug development.
- Spiro And Bicyclic Compound
- Hot sale various high quality spiro and bicyclic compound from china leading manufacturer. Our products are efficient, cost effective and deliver more benefits. welcome to choose us!
Column Infos
- ABBV-CLS-484
- Nature publishes discovery and preclinical results for ABBV-CLS-484, a potential first-in-class PTPN2/N1 inhibitor in cancer immunotherapy.
ABBV-CLS-484 is the first active-site phosphatase inhibitor to enter clinical evaluation as a cancer therapy and is currently in an AbbVie and Calico-led Phase 1 clinical trial in solid tumors.
Recherche 
+86 21 5895 0110 
